Henry Schein (NASDAQ:HSIC) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Henry Schein from “buy” to “hold,” while the broader analyst consensus is also “hold,” with an average price target of $92.27.
• Henry Schein reported quarterly EPS of $1.27, beating estimates by $0.03, while revenue reached $3.46 billion—up 6.7% year over year and above expectations.
• The stock opened at $88.13, near its 12-month high of $92.18; institutional investors own a substantial 96.62% of outstanding shares.

Henry Schein (NASDAQ:HSIC - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Sunday.

A number of other brokerages have also recently weighed in on HSIC. BTIG Research reaffirmed a "buy" rating and issued a $100.00 price target on shares of Henry Schein in a research report on Wednesday. Robert W. Baird set a $97.00 price objective on Henry Schein in a report on Wednesday, May 6th. Morgan Stanley reissued an "underweight" rating and issued a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Piper Sandler raised their price objective on Henry Schein from $91.00 to $95.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Finally, Barrington Research set a $104.00 target price on Henry Schein in a report on Wednesday. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $92.27.

Henry Schein Price Performance

NASDAQ HSIC opened at $88.13 on Friday. The company has a quick ratio of 0.75, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $9.82 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 1.68 and a beta of 0.80. Henry Schein has a 12-month low of $61.94 and a 12-month high of $92.18. The company has a 50 day moving average price of $83.49 and a two-hundred day moving average price of $78.67.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.03. The business had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. Henry Schein's revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, equities analysts predict that Henry Schein will post 5.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director William K. Daniel bought 10,000 shares of the business's stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.89% of the stock is owned by company insiders.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently made changes to their positions in the business. Invesco Ltd. grew its holdings in Henry Schein by 4.1% in the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company's stock valued at $314,043,000 after buying an additional 184,763 shares during the last quarter. Southpoint Capital Advisors LP lifted its holdings in shares of Henry Schein by 28.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company's stock worth $235,840,000 after buying an additional 700,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Henry Schein by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company's stock worth $211,734,000 after buying an additional 56,687 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Henry Schein by 11.3% in the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company's stock valued at $167,453,000 after acquiring an additional 256,156 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company's stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the period. Institutional investors and hedge funds own 96.62% of the company's stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source